Palliative Care Clinical Trials
Our team is dedicated to clinical research in the field of palliative care. For more information on any of these trials, or to find out if you're eligible to participate, contact Carolyn Revta, Palliative Care Clinical Research Operations Director, firstname.lastname@example.org or 858-822-3614.
Status: Currently recruiting
ClinicalTrials.gov identifier: NCT01619423
Eligible: Patients with metastatic colorectal cancer
The first line of treatment for patients with metastatic colorectal cancer is the combination chemotherapy FOLFOX (5–Fluorouracil, Leucovorin and Oxaliplatin), which is given as an intravenous (IV) infusion every two weeks. Although very effective in treating colorectal cancer, there are a number of side effects associated with this treatment regimen, including decreased white blood cell counts, sensory neuropathy of the hands and feet, and diarrhea. These side effects significantly impact a patient’s ability to tolerate treatment with FOLFOX and often result in dose reduction, dose delays, or early progression to a second line of chemotherapy. PledOx is an experimental drug designed to reduce the incidence and severity of these treatment related side effects. PledOx is a manganese-based treatment designed to reduce the toxic effects of chemotherapy in healthy cells. The goal of this open label phase II study is to assess the efficacy of two different doses of PledOx vs. placebo in protecting against side effects associated with the administration of FOLFOX in patients with metastatic colorectal cancer.
Palliative Care Clinical Research Operations Director
Moores Cancer Center